The FDA has approved the use of sublingual sufentanil (Dsuvia) to treat acute pain in adults in a medically supervised setting…
Search results for: hospital
5-Year Data on Secukinumab in AS; Oliceridine Not Recommended for FDA Approval
In a long-term study, secukinumab proved safe and effective for treating ankylosing spondylitis…
Protect Your Practice: Action Update From the ACR’s Insurance Subcommittee
Both private and academic rheumatology practices face payer challenges that put the health of their patients and their practices at risk. To make sure the rheumatologist perspective is heard by payers, “the ACR’s Insurance Subcommittee (ISC) serves as the interface between payers and our members and ACR colleagues,” explains Sean Fahey, MD, a rheumatologist in…
In Memoriam: Mart Mannik, MD
Mart Mannik, MD, professor emeritus, Division of Rheumatology at the University of Washington (UW), passed away on Wednesday, Aug. 22, 2018. Dr. Mannik was born in Estonia and came to the U.S. at age 12 as a refugee from World War II. He received his medical degree from Western Reserve University School of Medicine in…
CMS Proposes New Part B Drug Payment Model
Late last month, the Centers for Medicare & Medicaid Services (CMS) released an advance notice of proposed rulemaking (ANPRM), seeking feedback on a potential drug pricing model called the International Pricing Index (IPI) model. This comment solicitation is in alignment with the administration’s blueprint to lower drug costs and reduce out-of-pocket costs, and is an…
How to Engage Young Adult Patients
Gaps in healthcare are common between the ages of 17 and 21. But simple collaborations between adult and pediatric rheumatologists can go a long way to help young adults stay engaged in their rheumatology care…
FDA Approves Subcutaneous Tocilizumab for Ages 2–17
The FDA has approved subcutaneous tocilizumab for treating active systemic juvenile idiopathic arthritis in pediatric patients as young as 2 years old…
Q&A with New ACR President Paula Marchetta
Paula Marchetta, MD, MA, MBA, became a member of the ACR in 1989, during her rheumatology fellowship at Bellevue Hospital and the New York University (NYU) Medical Center. Just 10 years earlier, rheumatology had been an unlikely path. Dr. Marchetta—with a love of the arts—was pursuing Bachelor’s and Master’s degrees in English. But she found…
ACR Leaders Outline Advocacy Victories, Threats
CHICAGO—ACR leaders described a series of looming legislative and regulatory threats to rheumatologists and their patients—including the proposed collapsing of evaluation and management (E/M) coding and potential changes to step therapy rules—and urged everyone in the field to make their voices heard to quash the proposals. They also recounted recent victories in the policy realm…
Plaque Psoriasis Treatments: BMS-986165 Promising & Adalimumab Biosimilar Demonstrates Equivalence
According to new data, BMS-986165, an oral, selective tyrosine kinase 2 inhibitor, may be safe and effective for treating plaque psoriasis…
- « Previous Page
- 1
- …
- 134
- 135
- 136
- 137
- 138
- …
- 318
- Next Page »